Evaluating outcomes of a clinical pharmacist medication management program in a multidisciplinary practice for outpatient buprenorphine treatment of opioid use disorder

被引:8
|
作者
Mattle, Anna G. [1 ,2 ,3 ]
Aladeen, Traci [1 ,3 ]
Blondell, Richard D. [4 ]
Capote, Horacio [5 ]
Rainka, Michelle [1 ,3 ]
机构
[1] Univ Buffalo, Dept Pharm Practice, Buffalo, NY 14260 USA
[2] Univ Buffalo, Dept Pharmaceut Sci, Buffalo, NY 14260 USA
[3] Dent Neurol Inst, Div Neuropharmacol, Buffalo, NY 14226 USA
[4] Univ Buffalo, Dept Family Med, Buffalo, NY USA
[5] Dent Neurol Inst, Div Neuropsychiat, Buffalo, NY USA
关键词
addiction; buprenorphine; medications for opioid use disorder; medication-assisted treatment; multidisciplinary; opioids; opioid use disorder; outpatient; pharmacist; CARE;
D O I
10.1002/jac5.1405
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Introduction Treatment with medications such as buprenorphine has been shown to improve outcomes of patients with opioid use disorder (OUD); however, there is still potential to optimize care. Clinical pharmacists may benefit OUD patient treatment by making individualized medication recommendations and enhancing care as part of a multidisciplinary team. This study evaluates a novel outpatient practice model that incorporates pharmacists to manage OUD patients. Methods A multi-center retrospective study compared outcomes of a multidisciplinary practice with clinical pharmacists to a physician-only practice. Primary outcomes were treatment retention and opioid relapse rate. Secondary outcomes included patient engagement with counseling, toxicology results, and buprenorphine nonadherence. Data were collected from 75 patient records from each practice for up to 1 year after starting treatment. In addition, a prospective, observational study was conducted to describe pharmacist interventions at the multidisciplinary practice. Twenty patients were followed for up to 1 year to characterize pharmacist recommendations and assess treatment retention and opioid relapse rates among other secondary measures. Results In the retrospective study, treatment retention did not differ between practices (P > .05) but multidisciplinary practice patients experienced fewer opioid relapse months (P < .05). Similar rates of engagement with counseling (P = 1) and follow-up visits with illicit substance use (P > .05) were observed. More buprenorphine nonadherence was identified at the physician practice (P < .01). In the prospective study, pharmacist recommendations included buprenorphine regimen changes and the addition of new medications for un/undertreated conditions. Pharmacists provided care coordination, medication counseling, non-pharmacologic recommendations, and counseling regarding future/alternative treatment options. Conclusion This study demonstrates the ability of a practice with clinical pharmacists to provide quality care to OUD patients in an outpatient setting. These results have implications for OUD treatment by expanding addiction services in this underserved patient population.
引用
收藏
页码:424 / 434
页数:11
相关论文
共 50 条
  • [1] Hospital Buprenorphine Program for Opioid Use Disorder Is Associated With Increased Inpatient and Outpatient Addiction Treatment
    Christian, Nicholaus
    Bottner, Richard
    Baysinger, Amber
    Boulton, Alanna
    Walker, Blair
    Valencia, Victoria
    Moriates, Christopher
    [J]. JOURNAL OF HOSPITAL MEDICINE, 2021, 16 (06) : 345 - 348
  • [2] Buprenorphine treatment and clinical outcomes under the opioid use disorder cascade of care
    Williams, Arthur Robin
    Mauro, Christine M.
    Chiodo, Lisa
    Huber, Ben
    Cruz, Angelo
    Crystal, Stephen
    Samples, Hillary
    Nowels, Molly
    Wilson, Amanda
    Friedmann, Peter D.
    Remien, Robert H.
    Olfson, Mark
    [J]. DRUG AND ALCOHOL DEPENDENCE, 2024, 263
  • [3] MULTIDISCIPLINARY SUPPORT FOR BUPRENORPHINE-NALOXONE TREATMENT OF OPIOID USE DISORDER
    Hall, A.
    [J]. JOURNAL OF INVESTIGATIVE MEDICINE, 2020, 68 : A75 - A75
  • [4] Improving access to care via psychiatric clinical pharmacist practitioner collaborative management of buprenorphine for opioid use disorder
    Pals, Haley
    Bratberg, Jeffrey
    [J]. JOURNAL OF THE AMERICAN PHARMACISTS ASSOCIATION, 2022, 62 (04) : 1422 - 1429
  • [5] A Mobile Buprenorphine Treatment Program for Homeless Patients With Opioid Use Disorder
    Buzza, Colin
    Elser, Andrea
    Seal, Jeffrey
    [J]. PSYCHIATRIC SERVICES, 2019, 70 (07) : 635 - 636
  • [6] Therapy Dose Mediates the Relationship Between Buprenorphine/Naloxone and Opioid Treatment Outcomes in Youth Receiving Medication for Opioid Use Disorder Treatment
    Hammond, Christopher J.
    Kady, Annabel
    Park, Grace
    Vidal, Carol
    Wenzel, Kevin
    Fishman, Marc
    [J]. JOURNAL OF ADDICTION MEDICINE, 2022, 16 (02) : E97 - E104
  • [7] Non-prescribed buprenorphine preceding treatment intake and clinical outcomes for opioid use disorder
    Williams, Arthur Robin
    Mauro, Christine M.
    Feng, Tianshu
    Wilson, Amanda
    Cruz, Angelo
    Olfson, Mark
    Crystal, Stephen
    Samples, Hillary
    Chiodo, Lisa
    [J]. JOURNAL OF SUBSTANCE ABUSE TREATMENT, 2022, 139
  • [8] Project ECHO and primary care buprenorphine treatment for opioid use disorder: Implementation and clinical outcomes
    Anderson, James B.
    Martin, Stephen A.
    Gadomski, Anne
    Krupa, Nicole
    Mullin, Daniel
    Cahill, Amber
    Jenkins, Paul
    [J]. SUBSTANCE ABUSE, 2022, 43 (01) : 222 - 230
  • [9] Medication-Assisted Treatment for Opioid Use Disorder (OUD): Solving the Puzzle With Clinical Pharmacist Providers
    Wells, Ian
    [J]. JOURNAL OF PHARMACY PRACTICE, 2020, 33 (02) : 124 - 124
  • [10] A parenting education program for women in treatment for opioid-use disorder at an outpatient medical practice
    Kahn, Linda S.
    Mendel, Whitney E.
    Fallin, Kyla L.
    Borngraber, Elizabeth A.
    Nochajski, Thomas H.
    Rea, William E.
    Blondell, Richard D.
    [J]. SOCIAL WORK IN HEALTH CARE, 2017, 56 (07) : 649 - 665